Piramal Pharma Solutions and NP2 Near Completion of Cyclophosphamide Development

Piramal Pharma Solutions (PPS) and NP2 are on the brink of completing the development phase for the generic cancer drug cyclophosphamide this October. Conducted at PPS's sterile injectable facility in Lexington, Kentucky, this initiative addresses shortages and supply chain risks of cyclophosphamide, ensuring stable access for U.S. patients.

NP2, a nonprofit aiming to provide a consistent supply of life-saving cancer drugs, prioritizes a reliable U.S. manufacturing process. The ongoing expansion of PPS's Lexington facility, with an $85 million investment, aims to increase capacity for such critical medicines.

Amid alarming shortages in the EU and Canada, NP2 and PPS's collaboration solidifies a foundation for a robust domestic supply chain, allowing cancer patients to focus on treatment rather than drug availability.